Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines for the treatment of inflammatory and fibrotic diseases. It offers Filgotinib medication targeting rheumatoid arthritis (RA). The company is investigating GLPG3667 compound against autoimmune indications; GLPG2737, a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor to treat autosomal dominant polycystic kidney disease; GLPG1690, an oral autotaxin inhibitor targeting idiopathic pulmonary fibrosis (IPF); and GLPG1972 drug to treat osteoarthritis. Galapagos is also evaluating Filgotinib against Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, cutaneous lupus and uveitis. It has operational presence in the Netherlands, France, Germany, Italy, Spain, Switzerland, the United States and the United Kingdom. The company works in collaboration with disease foundations, pharmaceutical and biotechnology companies. Galapagos is headquartered in Mechelen, Belgium.

Headquarters Belgium

Address Generaal De Wittelaan 3, Malines (Mechelen), 2800


Telephone 32 15 342900

No of Employees 1,305

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange GLPG (AMS)

Revenue (2021) $636.9M 1.6% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 66.2% (2021 vs 2020)

Market Cap* $3.6B

Net Profit Margin (2021) XXX 66.7% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

150+

Clinical Trials

Determine Galapagos NV go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

110+

Catalyst Calendar

Proactively evaluate Galapagos NV’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

90+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Galapagos NV’s relevant decision makers and contact details.

70+

Pipeline Drugs

Identify which of Galapagos NV’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Galapagos NV’s commercialized product portfolio to stay one step ahead of the market.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
Filgotinib
GLPG3667
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company agreed to acquire CellPoint and AboundBio.
2022 Contracts/Agreements In May, the company exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra platform.
2022 Contracts/Agreements In April, the company announced a collaboration with e-therapeutics plc to receive additional milestone payments through pre-clinical and clinical development.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Galapagos NV TherapeuticsMD Inc Mithra Pharmaceuticals SA Oxurion NV Ablynx NV
Headquarters Belgium United States of America Belgium Belgium Belgium
City Malines (Mechelen) Boca Raton Liege Heverlee Ghent
State/Province - Florida - - Flandre Orientale
No. of Employees 1,305 416 248 42 450
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Paul Stoffels Chairman Executive Board 2022 -
Bart Filius President; Chief Financial Officer; Chief Operating Officer Senior Management 2021 51
Walid Abi-Saab, M.D. Chief Medical Officer Senior Management 2017 57
Piet Wigerinck, Ph.D. Chief Scientific Officer Senior Management 2012 58
Michele Manto Chief Commercial Officer Senior Management 2020 47
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer